Russian scientists have announced a new mRNA-based cancer vaccine called Enteromix, which has been reported to be promising during preclinical trials. Introduced during the Eastern Economic Forum, the vaccine is intended to cure such cancers as colorectal cancer, glioblastoma, and melanoma by making the immune system treat tumor cells as the enemy.
Russia Develops New mRNA-Based Cancer Vaccine “Enteromix”
The Cancer breakthrough
The creation of Enteromix, a clinically ready cancer vaccine, was announced by the Federal Medical and Biological Agency (FMBA) of Russia. The head of FMB, Veronika Skvortsova, announced the news at the 10th Eastern Economic Forum in Vladivostok, where representatives of more than 75 countries took part.
How Enteromix Works?
Much like COVID-19 vaccines, the vaccine is constructed using mRNA technology. It does not train the body’s cells to produce proteins specifically targeting cancer cells, as is taught by a weakened virus.
Preclinical Trials Results
- Senior preclinical testing completed.
- Safe even at repeated doses.
- Demonstrated 60-80% reduction in tumor size or growth rate, according to the type of cancer.
- Greater survival among test subjects.
First Focus: Colon Cancer
Enteromix will first be used to treat colorectal cancer, which is one of the most widespread large intestine cancers.
Expanding Research to Other Cancers
Researchers are also working on adapting the vaccine for:
- Glioblastoma (fast-growing brain cancer)
- Melanoma, including ocular melanoma (a rare eye cancer)
Enteromix can be the turning point in managing cancer. If clinical trials are successful, it could offer a better and safer alternative to traditional therapy, a hope for patients worldwide
